DEFA14A: Patterson Companies Amends Proxy Statement Following Shareholder Lawsuits Over Proposed Merger with Patient Square Capital

Patterson Companies updates its proxy statement to address shareholder lawsuits alleging insufficient disclosures regarding the merger with Patient Square Capital, aiming to avoid delays and associated costs.

Summary

• Patterson Companies is facing shareholder lawsuits and demand letters claiming the initial proxy statement for its merger with Patient Square Capital lacked material information.
• The lawsuits specifically target disclosures related to the sales process, financial projections, and financial analysis by the company's advisor, Guggenheim Securities.
• To avoid delaying the merger and minimize expenses, Patterson Companies is voluntarily supplementing the proxy statement with additional details.
• The supplemental disclosures include information about the non-disclosure agreements, fees payable to Guggenheim Securities, and details of the financial analysis.
• The board of directors continues to recommend shareholders vote in favor of the merger agreement.
• The special meeting of shareholders to vote on the merger is scheduled for April 1, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there are shareholder lawsuits, the company is proactively addressing them to ensure the merger proceeds. The board's recommendation to vote in favor of the merger is also a positive sign.

Positives

• Patterson Companies is proactively addressing shareholder concerns to ensure the merger proceeds smoothly.
• The company believes the original proxy statement was compliant but is providing additional information to avoid delays.
• The board of directors unanimously (excluding the CEO) recommends shareholders vote in favor of the merger.

Negatives

• Shareholder lawsuits and demand letters indicate concerns about the adequacy of disclosures in the initial proxy statement.
• The need to supplement the proxy statement suggests potential weaknesses in the original disclosures.
• The lawsuits could potentially delay or disrupt the merger process, although the company is trying to mitigate this risk.

Risks

• The inability to consummate the merger within the anticipated time period, or at all, due to various factors including failure to obtain regulatory and shareholder approvals or complete financing arrangements.
• The risk that the merger disrupts current plans and operations or diverts management's attention.
• The effects of the merger on the business, operating results, and ability to retain and hire key personnel.
• The risk that the stock price may decline significantly if the merger is not consummated.
• The nature, cost and outcome of any legal proceedings related to the merger.

Future Outlook

The company is focused on completing the merger with Patient Square Capital, but the forward-looking statements caution that actual results could differ materially due to various risks and uncertainties.

Management Comments

• Patterson's board of directors unanimously (with Donald J. Zurbay, Chief Executive Officer and Director of the Company, having recused himself) recommends that you vote FOR the proposal to adopt and approve the Merger Agreement and the transactions contemplated thereby, including the Merger.
• The Company believes the complaints and demands are without merit, that the Proxy Statement fully complies with the Securities Exchange Act of 1934, and all other applicable law, and that no further disclosure is required.
• Solely to avoid the risk of delaying or otherwise adversely affecting the consummation of the Merger and to minimize the expense and distraction of defending any potential actions, Patterson hereby voluntarily amends and supplements the Proxy Statement.

Industry Context

The document references precedent transactions and premiums paid in the healthcare services sector, providing context for the valuation of Patterson Companies in the merger.

Comparison to Industry Standards

• The document includes a table of premiums paid in selected healthcare services merger and acquisition transactions, providing a benchmark for the premium offered to Patterson Companies' shareholders.
• The analysis considers various metrics such as one-day premium, 30-day VWAP premium, and 52-week high premium, comparing Patterson's deal to industry averages.
• Comparable transactions include acquisitions of companies like Avid Bioservices, Agiliti, Catalent, and Amedisys.
• The premiums paid in these transactions range widely, with some exceeding 100% and others showing discounts to the 52-week high.

Legal Proceedings

• Two substantially similar actions have been filed by purported Company shareholders against the Company and the Company's board of directors.
• The complaints and demand letters allege failures to disclose material information in the Proxy Statement, which allegedly rendered the Proxy Statement false and misleading.
• The complaints seek to enjoin the Merger unless and until the alleged omitted material information is disclosed and/or rescissory damages, compensatory damages, attorneys fees and other litigation costs.

Stakeholder Impact

• Shareholders are directly impacted by the merger and the potential for increased value or disruption.
• Employees face uncertainty regarding their future roles and employment terms post-merger.
• Customers and suppliers may experience changes in business relationships and operations following the merger.

Next Steps

• Shareholders will vote on the merger agreement at the special meeting on April 1, 2025.
• The company will continue to address any legal challenges related to the merger.
• The company may enter into new agreements or amendments to existing arrangements with Parent or one of its affiliates regarding their employment with the Company after the Merger.

Key Dates

Keywords

Merger Agreement, Proxy Statement, Patterson Companies, Patient Square Capital, Shareholder Litigation, Merger, Disclosures, Financial Analysis